Search Within

Advanced Practice Providers

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Journal Article (61)
  2. Meeting Abstract (56)
  3. Miscellaneous (4)
  4. Research Letter (3)
  5. Review (3)
  6. Conference Paper (2)
  7. Editorial (1)
Groups
  1. Sloan Kettering Institute Postdocs (130)
  2. Department of Medicine (77)
  3. Nursing (68)
  4. Survivorship Research (67)
  5. GSK Faculty (58)
  6. Department of Pathology and Laboratory Medicine (50)

More Groups

People
  1. Ahmet Dogan (22)
  2. Gunjan Shah (17)
  3. Maria Arcila (17)
  4. Alison Moskowitz (15)
  5. Malin Hultcrantz (15)
  6. Maria Palomba (15)

More People

Years
  1. 2025 (2)
  2. 2024 (15)
  3. 2023 (16)
  4. 2022 (19)
  5. 2021 (16)
  6. 2020 (17)

More Years

Publications
  1. Blood (25)
  2. Journal of Clinical Oncology (13)
  3. Annals of Surgical Oncology (11)
  4. Neuro-Oncology (7)
  5. Annals of Surgery (4)
  6. BJU International (3)

More Publications

Publishers
  1. American Society of Hematology (26)
  2. Springer (16)
  3. American Society of Clinical Oncology (13)
  4. Lippincott Williams & Wilkins (11)
  5. Oxford University Press (11)
  6. Elsevier Science, Inc. (9)

More Publishers

Results (130)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ASO Visual Abstract: Comparison of outcomes for classic-type lobular carcinoma in situ managed with surgical excision after core biopsy versus observation
    Miscellaneous

    Matar, R.; Sevilimedu, V.; Park, A.; King, T. A.; Pilewskie, M.
    Annals of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • Accuracy, sensitivity, and specificity of the LLIS and ULL27 in detecting breast cancer-related lymphedema
    Journal Article

    Coriddi, M.; Kim, L.; McGrath, L.; Encarnacion, E.; Brereton, N.; Shen, Y.; Barrio, A. V.; Mehrara, B.; Dayan, J. H.
    Annals of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Quantifying intrathecal drug delivery utilizing programmable ventriculoperitoneal shunts
    Meeting Abstract

    McThenia, S.; Pandit-Taskar, N.; Grkovski, M.; Donzelli, M.; Diagana, S.; Greenfield, J.; Souweidane, M.; Kramer, K.
    Neuro-Oncology Advances (2021)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • ASO Visual Abstract: Accuracy, sensitivity, and specificity of the LLIS and ULL27 in detecting breast cancer-related lymphedema
    Miscellaneous

    Coriddi, M.; Kim, L.; McGrath, L.; Encarnacion, E.; Brereton, N.; Shen, Y.; Barrio, A. V.; Mehrara, B.; Dayan, J. H.
    Annals of Surgical Oncology (2021)

    Fulltext@MSK | Save
  • Positron emission tomography-computed tomography imaging, genomic profile, and survival in patients with head and neck cancer receiving immunotherapy
    Research Letter

    Fitzgerald, C. W. R.; Valero, C.; Swartzwelder, C. E.; Morris, L. G. T.
    JAMA Otolaryngology - Head and Neck Surgery (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save